US Established Zero-Duty Framework for Pharma Imports
Specialty pharmaceutical producers in India and 19 partner countries are now exempt from 100 per cent import tariffs.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Should the U.S. prioritize zero-duty trade agreements to lower the cost of imported prescription drugs?
The United States Commerce Department has published a framework allowing zero-duty status for specific specialty pharmaceutical products from India and 19 other nations. This policy shift provides relief for makers of rare disease treatments and advanced therapies following the imposition of 100 per cent import duties on patented drugs earlier this year.
Why it matters
The measure is designed to incentivize greater domestic manufacturing of pharmaceutical products within the United States. For global operators, the change recalibrates cost structures for high-end medical goods and clarifies compliance requirements for those navigating the existing tariff regime.
The 100 per cent import duty on specified patented drugs and biologics was initially established on April 2, 2026. Following the latest exemption announcement, the Nifty Pharma index registered at 26,831.60.
The players
United States Commerce Department
The federal agency responsible for trade regulation, industrial policy, and the administration of import tariffs.
President Donald Trump
The current President of the United States who signed the April 2026 directive on pharmaceutical imports.
The details
Under the new framework, qualifying imports including medicines for rare conditions, fertility treatments, and cell and gene therapies receive zero-duty treatment. Generic pharmaceutical products and their constituent ingredients remain outside the scope of the original 100 per cent Section 232 tariffs. Manufacturers must align with specific security framework agreements with Washington to qualify for the exemption status.
Timeline
President Trump signed the initial directive on pharmaceutical imports on April 2, 2026.
Tariffs took effect for companies in the initial annex on July 31, 2026.
The zero-duty exemption framework was announced on September 29, 2026.
Tariffs were extended to other listed companies on September 29, 2026.
Market Landscape
The new duty exemption framework follows the pattern of enforcement and subsequent strategic adjustment established by the Section 232 pharmaceutical tariffs. This policy update marks a strategic pivot to provide targeted relief within the existing import restriction regime.
Operators in the specialty pharmaceutical sector should review the newly published Federal Register list to determine if their products qualify for duty-free status. Firms should consult with trade counsel to ensure their specific biologics or specialty therapies meet the security agreement requirements.
The takeaway
The move suggests a shifting priority toward shielding high-value specialty medicine supply chains while maintaining strict oversight on broader patent-protected drugs. Operators should verify their current tariff exposure against the new exemption annexes published by the Commerce Department.
Further reading
For broader trends in pharmaceutical trade, see Healthcare.
Source note: This article includes information reported by Zee Business.
Live Poll
Should the U.S. prioritize zero-duty trade agreements to lower the cost of imported prescription drugs?
